Last reviewed · How we verify
NCT04020744
Real-time fMRI Neurofeedback in Patients With MCI
NA trial testing real-time fMRI based neurofeedback from the hippocampus in Mild Cognitive Impairment in 84 participants. Completed in 31 January 2024.
31 October 2023
Quick facts
| Lead sponsor | University of Bern |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 84 |
| Start date | 1 July 2020 |
| Primary completion | 31 October 2023 |
| Estimated completion | 31 January 2024 |
| Sites | 2 locations across Switzerland |
Drugs / interventions tested
- real-time fMRI based neurofeedback from the hippocampus
- real-time fMRI based neurofeedback from another brain area
Conditions studied
- Mild Cognitive Impairment — all drugs for Mild Cognitive Impairment →
Sponsor
University of Bern
Who can join
Adults 60 to 80, any sex, with Mild Cognitive Impairment. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Increased activity in the hippocampus (i.e., hyperactivity) during a fMRI memory task was found in patients with Mild Cognitive Impairment due to Alzheimer's disease (MCI). Those with increased hippocampal activity exhibited elevated clinical progression. Reducing hippocampal hyperactivity with pharmacological treatment reduced hyperactivity and improved memory performance. The investigators of this study will test whether real-time fMRI neurofeedback will also downregulate hippocampal activity and thereby improve memory performance.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Targeting hippocampal hyperactivity with real-time fMRI neurofeedback: protocol of a single-blind randomized controlled trial in mild cognitive impairment.
Klink K, Jaun U, Federspiel A, Wunderlin M, et al · · 2021 · cited 13× · PMID 33563242 · DOI 10.1186/s12888-021-03091-8 -
Downregulation of hippocampal activity improves memory performance in individuals at risk of Alzheimer’s disease
Klink K, Lysser Y, Wunderlin M, Radojewski P, et al · · 2025 · cited 1× · DOI 10.1101/2025.10.14.25333311
Verify or expand the search:
- PubMed search for NCT04020744
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Mild Cognitive Impairment
Currently open trials in the same condition.
- NCT05791994 — EVASION: Effect of VisuAl Stimulation on attentION · NA · recruiting
- NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
- NCT07220694 — Effects of Sabroxy® Supplementation on Insulin Resistance and Cognitive Function in Adults With Mild Cognitive Impairmen · NA · recruiting
- NCT06983769 — CPAP vs MAD for OSA in Patients With Cognitive Impairment. A Randomized Clinical Trial · NA · recruiting
- NCT07318038 — The Use of Rhythmic Light Therapy in Mild Cognitive Impairment · NA · recruiting
Other University of Bern trials
Trials by the same sponsor.
- NCT05940662 — Cost Effectiveness of Various Implant Placement Protocols in the Esthetic Zone · Phase 4 · suspended
- NCT02919163 — Systematically Assessing Effects of Colored Light on Humans With a Multi-modal Approach (Substudy 6 of 7) · NA · not yet recruiting
- NCT02919189 — Systematically Assessing Effects of Colored Light on Humans With a Multi-modal Approach (Substudy 5 of 7) · NA · not yet recruiting
- NCT04817592 — Characterization of the Corneal Biomechanics of Patients Treated by Corneal Lenticule Extraction for Advanced Refractive · not yet recruiting
- NCT06806150 — The INSPIRE Study: INvestigation of Swiss Physicians Inner-life, Resilience, and Emotions · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04020744 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Bern
- Last refreshed: 8 May 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04020744.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing